A recent study in Stanford Medicine highlighted that “completely surprised” researchers could be a promising approach to speeding up Parkinson’s disease Progress.
A study published in the Journal Science Signaling examined the role of enzymes (internal proteins essential for chemical reactions, liver function and other important functions) and Parkinson’s disease, according to the Cleveland Clinic.
The team discovered that targeting specific enzymes can help restore communication between mouse neurons and cells.
Deep brain stimulation of the brain improves symptoms for music conductors with Parkinson’s disease
The lead author, Dr. Suzanne Pfefer, professor of medical science, Emma Pfeiffer Manor and professor of biochemistry at Stanford University, told Fox News Digital that the team was “completely surprised to see the improvements we did.”
Approximately 25% of cases of Parkinson’s disease, the perpetrator is in some form Genetic variation. According to a Stanford press release, one of the most common mutations creates an overactive enzyme called LRRK2.
If there are too many LRRK2 activities, Brain cellsdisrupts important communication between neurons and cells. Researchers say the system is essential for movement, motivation and decision-making.
The goal of this study was to determine whether a particular molecule (the MLI-2 LRRK2 kinase inhibitor) could reverse the effect of an overactive enzyme.
Parkinson’s patients taking “magic mushrooms” see important benefits, according to research
Using mice with gene mutations that caused LRRK2 overactivity and have symptoms consistent with early Parkinson’s disease, scientists tried to feed the inhibitor for two weeks.
Initially, no changes were detected in the brain structure, signals, or function of dopamine neurons.
However, after taking the inhibitor for three months, mice affected by the overactive enzyme appeared to restore neurons in virtually the same way as those without genetic mutations, the study found.
“The findings from this study suggest that inhibiting the LRRK2 enzyme may stabilize the progression of symptoms if the patient can be identified quickly enough,” Pfeffer said in a press release.
The study had several limitations, the researchers acknowledged.
“This was in mice, not people, but the current results show that similar pathways are important in humans,” Pfeffer told Fox News Digital.
Although this study focused on specific genetic forms of disease, hyperactive LRRK2 is also present in other cases. This means that this treatment could be useful in multiple types of Parkinson’s disease patients, and perhaps with others. Neurodegenerative diseasesthe person in charge argued.
In the future, the team will investigate whether other forms of Parkinson’s disease can benefit from it.
Click here to sign up for our health newsletter
According to the Parkinsonson Foundation, which has offices in New York and Miami, Parkinson’s disease – a disease that involves the slow death of dopamine-producing neurons, leads to symptoms such as tremors and stiffness – affects about 1 million Americans.
Experts agree that early intervention is important as symptoms of Parkinson’s disease appear many years after the illness begins.
Identifying and treating at-risk individuals earlier may halt or reverse neuronal loss.
“These findings suggest that not only can it stabilize the condition of Parkinson’s patients, but it may be possible to improve it,” Pfeffer said.
Visit us for more health articles www.foxnews.com/health
The researchers told Fox News Digital it is important to encourage patients to undergo genetic testing to learn more about their clinical trials and compatibility with clinical trials. Future treatment.
This study was funded by the Michael J. Fox Foundation for Parkinson’s Disease, the Parkinson’s Initiative and the Michael J. Fox Foundation for Integrated Science at the UK Medical Research Council.
